BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15713462)

  • 1. Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations.
    Dumoulin M; Canet D; Last AM; Pardon E; Archer DB; Muyldermans S; Wyns L; Matagne A; Robinson CV; Redfield C; Dobson CM
    J Mol Biol; 2005 Feb; 346(3):773-88. PubMed ID: 15713462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils.
    Chan PH; Pardon E; Menzer L; De Genst E; Kumita JR; Christodoulou J; Saerens D; Brans A; Bouillenne F; Archer DB; Robinson CV; Muyldermans S; Matagne A; Redfield C; Wyns L; Dobson CM; Dumoulin M
    Biochemistry; 2008 Oct; 47(42):11041-54. PubMed ID: 18816062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.
    De Genst E; Chan PH; Pardon E; Hsu SD; Kumita JR; Christodoulou J; Menzer L; Chirgadze DY; Robinson CV; Muyldermans S; Matagne A; Wyns L; Dobson CM; Dumoulin M
    J Phys Chem B; 2013 Oct; 117(42):13245-13258. PubMed ID: 23919586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme.
    Canet D; Last AM; Tito P; Sunde M; Spencer A; Archer DB; Redfield C; Robinson CV; Dobson CM
    Nat Struct Biol; 2002 Apr; 9(4):308-15. PubMed ID: 11887182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of the structural, dynamic and aggregation properties of the W64R amyloidogenic variant of human lysozyme.
    Vettore N; Moray J; Brans A; Herman R; Charlier P; Kumita JR; Kerff F; Dobson CM; Dumoulin M
    Biophys Chem; 2021 Apr; 271():106563. PubMed ID: 33640796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of the Location of Mutations for the Native-State Dynamics of Human Lysozyme.
    Ahn M; Hagan CL; Bernardo-Gancedo A; De Genst E; Newby FN; Christodoulou J; Dhulesia A; Dumoulin M; Robinson CV; Dobson CM; Kumita JR
    Biophys J; 2016 Dec; 111(11):2358-2367. PubMed ID: 27926837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosis.
    Hagan CL; Johnson RJ; Dhulesia A; Dumoulin M; Dumont J; De Genst E; Christodoulou J; Robinson CV; Dobson CM; Kumita JR
    Protein Eng Des Sel; 2010 Jul; 23(7):499-506. PubMed ID: 20382744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationalising lysozyme amyloidosis: insights from the structure and solution dynamics of T70N lysozyme.
    Johnson RJ; Christodoulou J; Dumoulin M; Caddy GL; Alcocer MJ; Murtagh GJ; Kumita JR; Larsson G; Robinson CV; Archer DB; Luisi B; Dobson CM
    J Mol Biol; 2005 Sep; 352(4):823-36. PubMed ID: 16126226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.
    Dumoulin M; Last AM; Desmyter A; Decanniere K; Canet D; Larsson G; Spencer A; Archer DB; Sasse J; Muyldermans S; Wyns L; Redfield C; Matagne A; Robinson CV; Dobson CM
    Nature; 2003 Aug; 424(6950):783-8. PubMed ID: 12917687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants.
    Canet D; Sunde M; Last AM; Miranker A; Spencer A; Robinson CV; Dobson CM
    Biochemistry; 1999 May; 38(20):6419-27. PubMed ID: 10350460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulations of human lysozyme: probing the conformations triggering amyloidosis.
    Moraitakis G; Goodfellow JM
    Biophys J; 2003 Apr; 84(4):2149-58. PubMed ID: 12668424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.
    Booth DR; Sunde M; Bellotti V; Robinson CV; Hutchinson WL; Fraser PE; Hawkins PN; Dobson CM; Radford SE; Blake CC; Pepys MB
    Nature; 1997 Feb; 385(6619):787-93. PubMed ID: 9039909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure.
    De Felice FG; Vieira MN; Meirelles MN; Morozova-Roche LA; Dobson CM; Ferreira ST
    FASEB J; 2004 Jul; 18(10):1099-101. PubMed ID: 15155566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly amyloidogenic region of hen lysozyme.
    Frare E; Polverino De Laureto P; Zurdo J; Dobson CM; Fontana A
    J Mol Biol; 2004 Jul; 340(5):1153-65. PubMed ID: 15236974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the conformational changes of several human lysozyme variants associated with hereditary systemic amyloidosis.
    Liu HL; Wu YC; Zhao JH; Liu YF; Huang CH; Fang HW; Ho Y
    Biotechnol Prog; 2007; 23(1):246-54. PubMed ID: 17269695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants.
    Morozova-Roche LA; Zurdo J; Spencer A; Noppe W; Receveur V; Archer DB; Joniau M; Dobson CM
    J Struct Biol; 2000 Jun; 130(2-3):339-51. PubMed ID: 10940237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy.
    Chamberlain AK; Receveur V; Spencer A; Redfield C; Dobson CM
    Protein Sci; 2001 Dec; 10(12):2525-30. PubMed ID: 11714920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elongation in a beta-structure promotes amyloid-like fibril formation of human lysozyme.
    Goda S; Takano K; Yamagata Y; Maki S; Namba K; Yutani K
    J Biochem; 2002 Oct; 132(4):655-61. PubMed ID: 12359083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative folding of the isolated alpha-helical domain of hen egg-white lysozyme.
    Bai P; Peng Z
    J Mol Biol; 2001 Nov; 314(2):321-9. PubMed ID: 11718563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR structural study of two-disulfide variant of hen lysozyme: 2SS[6-127, 30-115]--a disulfide intermediate with a partly unfolded structure.
    Noda Y; Yokota A; Horii D; Tominaga T; Tanisaka Y; Tachibana H; Segawa S
    Biochemistry; 2002 Feb; 41(7):2130-9. PubMed ID: 11841203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.